Validation of a Tear-based Screening Assay for Breast Cancer

Breast Cancer, Breast Cancer Female, Health Care Acceptability, Health Care Utilization, Health Knowledge, Attitudes, Practice, Health Personnel Attitude, Healthy

preventative screening, protein biomarkers, lacrimal tear fluid, mammography, primary care, ELISA assay, CLIA laboratory, lab developed test, clinical utility, high complexity, underserved populations, health disparities, tear collection, mammogram, improved patient outcomes, reduces gap in access, health equity, total cost of care, trust from patient, increased compliance, affordable, non-invasive, women's health and wellness, breast health, breast cancer screening test

This study will explore and better understand the value, usage, and benefits of a tear-based screening test for breast cancer as a supplemental tool for screening mammograms. This tear-based screening test was developed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.

The primary objective of this study is to determine if a tear-based biological test is an effective option in breast cancer screening. This will be assessed by comparing the score and classification produced from the assay to the current gold standard, screening Mammograms. The primary endpoint will be assessed by calculating the sensitivity, specificity, PPV, and NPV for the biological assay compared to the results of imaging. The secondary objective of this study is to obtain provider insight and recommendation as to the potential clinical utility of a tear-based biological test as a breast cancer screening option. The secondary endpoint will be achieved through a provider roundtable discussion. After completion of enrollment and evaluation of tear samples and time will be arranged, either in person or virtual, to review the test scores determined for the sites patient population. Providers will be allowed to verbally review the process and give their thoughts on the utility of a tear-based biological test within their clinic and how they feel it should be used. A member of the Namida Lab clinical team will be present to take notes. After the discussion a report will be generated and the site providers will be allowed to review it for accuracy. Sites will be given a copy of their participants' scores as well as a summary of the provider roundtable discussion. Sites may request to have the participants' results blinded if prior to review if preferred.

No related papers found yet.

United States